Pfizer Inc
USUSDPfizer Inc (MX:PFE) — Biotechnology: Pharmaceutical Preparations. Liczba giełd, na których notowane są akcje spółki: 4. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
- Pfizer Limited — PFIZER · NSE IN ISIN INE182A01018
O Firmie
- Strona
- pfizer.com
- Relacje Inwestorskie
- investors.pfizer.com/overview/default.aspx
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Siedziba
- New York City, United States
- Prezes
- Albert Bourla
- Pracownicy
- 88 300
- Założona
- 1849
- Notowana od
- 12.04.2004 (MX:PFE)
- Akcje w Obrocie
- Free Float
- 5.69 mld
- Kapitalizacja Rynkowa
- 162.55 mld USD
- Insiderzy
- 0.1%
- Inwestorzy Instytucjonalni
- 69.12%
- Branża (SIC)
- Pharmaceutical Preparations
- Forma Prawna
- XTIQ
- ISIN
- US7170811035
- LEI
- 765LHXWGK1KXCLTFYQ30
- P/E
- 39.5
- Stopa Wypłaty
- 226%
- FCF
- 11.0 mld USD
- Wypłaty / FCF
- 89%
- Dług
- 63.1 mld USD5.7 l. FCF
- Staż Dywidendowy
- 54 l.
- Zysk, FCF i wypłacone dywidendy — za 12 miesięcy do 28.06.2026 (najnowszy raport spółki).
- NAV
Opis
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Dywidendy
Pfizer Inc (PFE) wypłaca dywidendy kwartalnie. Na rok (12 miesięcy do ostatniej ogłoszonej płatności): 1.72 USD na akcję (płatności: 4). To około 5.89% obecnej ceny akcji. Następna data ex-dywidendy to 06.11.2026: 0.43 USD na akcję, wypłata 07.12.2026. Lata nieprzerwanych dywidend: 54.
| Dzień Ex | Wypłata | Kwota | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-11-06 ogłoszona | 2026-12-07 | 0.4300 USD | 1.5/5.9 % | kwartalnie | US:PFE |
| 2026-07-24 | 2026-09-01 | 0.4300 USD | 1.7/6.9 % | kwartalnie | US:PFE |
| 2026-05-08 | 2026-06-12 | 0.4300 USD | 1.6/6.5 % | kwartalnie | US:PFE |
| 2026-01-23 | 2026-03-06 | 0.4300 USD | 1.6/6.6 % | kwartalnie | US:PFE |
| 2025-11-07 | 2025-12-01 | 0.4300 USD | 1.7/6.9 % | kwartalnie | US:PFE |
| 2025-07-25 | 2025-09-02 | 0.4300 USD | 1.7/6.7 % | kwartalnie | US:PFE |
| 2025-05-09 | 2025-06-13 | 0.4300 USD | 1.9/7.4 % | kwartalnie | US:PFE |
| 2025-01-24 | 2025-03-07 | 0.4300 USD | 1.6/6.4 % | kwartalnie | US:PFE |
| 2024-11-08 | 2024-12-02 | 0.4200 USD | 1.5/6.1 % | kwartalnie | US:PFE |
| 2024-07-26 | 2024-09-03 | 0.4200 USD | 1.7/6.6 % | kwartalnie | US:PFE |
| 2024-05-09 | 2024-06-14 | 0.4200 USD | 1.7/6.5 % | kwartalnie | US:PFE |
| 2024-01-25 | 2024-03-01 | 0.4200 USD | 1.5/5.7 % | kwartalnie | US:PFE |
| 2023-11-09 | 2023-12-04 | 0.4100 USD | 1.3/5.3 % | kwartalnie | US:PFE |
| 2023-07-27 | — | 0.4100 USD | 1.1/4.4 % | kwartalnie | US:PFE |
| 2023-05-11 | — | 0.4100 USD | 1.1/4.4 % | kwartalnie | US:PFE |
| 2023-01-26 | — | 0.4100 USD | 0.9/3.6 % | kwartalnie | US:PFE |
| 2022-11-03 | — | 0.4000 USD | 0.8/3.4 % | kwartalnie | US:PFE |
| 2022-07-28 | — | 0.4000 USD | 0.8/3.1 % | kwartalnie | US:PFE |
| 2022-05-12 | — | 0.4000 USD | 0.8/2.4 % | kwartalnie | US:PFE |
| 2022-01-27 | — | 0.4000 USD | 0.8/1.5 % | kwartalnie | US:PFE |
| 2021-11-04 | — | 0.3900 USD | 0.9/0.9 % | kwartalnie | US:PFE |
Najwięksi Akcjonariusze
| Posiadacz | Udział | Akcje | Data Raportu |
|---|---|---|---|
| BlackRock | 9.29% | 529.67 mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 372.15 mln | 2026-06-30 |
| State Street Corporation | 5.39% | 307.09 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 180.94 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 147.7 mln | 2026-06-30 |
| Geode Capital Management… | 2.37% | 135.28 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.09% | 119.24 mln | 2026-06-30 |
| Fisher Asset Management,… | 1.91% | 109.07 mln | 2026-06-30 |
| Morgan Stanley | 1.69% | 96.35 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 75.86 mln | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 73.7 mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 69.68 mln | 2026-08-31 |
| NORGES BANK | 1.08% | 61.51 mln | 2026-06-30 |
| Northern Trust Corporati… | 1.04% | 59.08 mln | 2026-06-30 |
| Bank Of New York Mellon… | 1.02% | 57.88 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 54.25 mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 40.97 mln | 2026-08-31 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 30.94 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 0.45% | 25.75 mln | 2026-08-31 |
| VANGUARD WHITEHALL FUNDS… | 0.4% | 22.92 mln | 2026-07-31 |
| BOURLA ALBERT (Chief Exe… | ≈0.01% | 435 555 | 2026-08-12 |
| SUSMAN SALLY (Officer) | ≈0% | 169 775 | 2025-02-27 |
| LANKLER DOUGLAS M (Offic… | ≈0% | 165 260 | 2026-02-25 |
| BOSHOFF CHRISTOFFEL (Off… | ≈0% | 162 088 | 2026-02-25 |
| MCDERMOTT MICHAEL (Offic… | ≈0% | 74 308 | 2026-02-25 |
| BLAYLOCK RONALD E (Direc… | ≈0% | 71 688 | 2026-08-05 |
| FONSECA LIDIA PH.D. (Off… | ≈0% | 46 455 | 2026-02-25 |
| SAHNI PAYAL (Officer) | ≈0% | 42 297 | 2026-02-25 |
| BUCKLEY MORTIMER J. (Dir… | ≈0% | 37 632 | 2026-08-05 |
| DAMICO JENNIFER B. (Offi… | ≈0% | 28 611 | 2026-08-05 |
| The Vanguard Group | — | — | — |
